Abstract: The present disclosure relates a method for reducing animal weight, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a mulberry extract. The mulberry extract comprises: 3% to 99% of an alkaloid, 0.2% to 70% of a polysaccharide, 0% to 50% of an amino acid, 0% to 10% of flavone, and 0% to 25% of other components. The mulberry extract of the present disclosure can be used for controlling weight gain, and has a good therapeutic effect on type 2 diabetes with obesity.

Abstract: The present disclosure relates to the field of pharmaceutical technology, providing three crystalline forms, i.e., a crystalline form AB, a crystalline form M and a crystalline form F, of the compound 6-[[4-[2-fluoro-4-[[1-[(4-fluorophenyl)aminoformyl]cyclopropanecarbonyl]-amino]phenoxy]-6-methoxy-7-quinolyl]oxy]hexanoic acid for treatment of diseases related to protein kinases AXL and/or VEGFR2. The present disclosure also provides methods for preparing these three crystalline forms and pharmaceutical compositions comprising these three crystalline forms. The crystalline form AB, the crystalline form M and the crystalline form F of the present disclosure all have good chemical stability, and the preparation processes of the three crystalline forms of the present disclosure are simple for implementation with high product yield and purity, allowing stable and mass production that facilitates promotion and application.